S1PR1 and inflammatory bowel disease: In particular, anti-tumor necrosis factor agents have been consistently linked to new-onset or worsening demyelinating events, while other treatments such as sphingosine-1-phosphate receptor modulators and natali­zumab are licensed for both IBD and MS, though real-world data in patients with coexisting disease remain limited.